CureVac NV (CureVac NV) EBITDA Margin % : -522.75% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CureVac NV's EBITDA for the three months ended in Mar. 2024 was $-70.30 Mil. CureVac NV's Revenue for the three months ended in Mar. 2024 was $13.45 Mil. Therefore, CureVac NV's EBITDA margin for the quarter that ended in Mar. 2024 was -522.75%.

CureVac NV EBITDA Margin % Historical Data

The historical data trend for CureVac NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV EBITDA Margin % Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-525.39

-198.63

-375.26

-328.85

-435.45

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-709.96	-791.27	-234.67	-375.88	-522.75

Competitive Comparison of CureVac NV's EBITDA Margin %

For the Biotechnology subindustry, CureVac NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CureVac NV's EBITDA Margin % falls into.

CureVac NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CureVac NV's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-255.278	/	58.624
	=	-435.45 %

CureVac NV's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-70.304	/	13.449
	=	-522.75 %

CureVac NV (NAS:CVAC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CureVac NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of CureVac NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.